A randomized, double-blinded, placebo-controlled subcutaneously-administered multi-dose Phase 2b trial of ANB020 in moderate-to-severe baseline adult peanut allergy patients
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Etokimab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- 07 Aug 2018 According to an AnaptysBio media release, the company has decided to deprioritize further the company-sponsored clinical development of Etokimab in peanut allergy patients, as , the company is not intent to use its resources to pursue a Phase 2b clinical trial of etokimab in peanut allergy.
- 08 May 2018 According to an AnaptysBio media release, the Company anticipates that severity symptoms of all patients in the trial will be adjudicated during baseline and post-treatment oral food challenges by an independent, blinded assessor in accordance with PRACTALL guidelines, and any patients that demonstrate mild severity of symptoms at baseline will be excluded from enrollment in the trial.
- 02 Apr 2018 New trial record